The chronic autoimmune neuropathies are a diverse group of disorders, whose diagnosis and classification is based on the clinical presentations and results of ancillary tests. In chronic inflammatory demyelinating polyneuropathy, controlled therapeutic trials demonstrated efficacy for intravenous gamma-globulins, corticosteroids, and plasmaphereis. In multifocal motor neuropathy, intravenous gamma-globulins have been shown to be effective. In the other immune-mediated neuropathies, there are no reported controlled therapeutic trials, but efficacy has been reported for some treatments in non-controlled trials on case studies. Choice of therapy in individual cases is based on reported efficacy, as well as severity, progression, coexisting illness, predisposition to developing complications, and potential drug interactions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.cnd.0000205575.26451.e4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Co-Existent Central and Peripheral Demyelination: Related or Coincidental?
Neurol Int
December 2024
Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Background: Hereditary Sensory Motor Neuropathy (HSMN) 1A and Multiple Sclerosis (MS) are distinct demyelinating disorders affecting the peripheral and central nervous systems, respectively. We present a case of simultaneous occurrence of both conditions, exploring the clinical presentation, diagnostic workup, and potential interplay between these diseases. Case presentation and clinical approach: A 49-year-old male with a history of optic neuritis presented with progressive numbness, weakness, and sensory loss in all extremities over four years.
View Article and Find Full Text PDFInflammatory Markers and Measures of Cardiovascular Autonomic Neuropathy in Type 1 Diabetes.
J Am Heart Assoc
December 2024
Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes University of Michigan Ann Arbor MI USA.
Background: Cardiovascular autonomic neuropathy (CAN) and inflammation predict more severe outcomes in type 1 diabetes (T1D). However, the link between CAN and inflammation in T1D remains unclear. We examined associations between CAN measures and inflammatory biomarkers in individuals with T1D.
View Article and Find Full Text PDFFavorable long-term outcomes of autoimmune nodopathy with mycophenolate mofetil.
Front Neurol
December 2024
Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Autoimmune nodopathy (AN) is a rare immune-mediated neuropathy characterized by autoantibodies against nodal or paranodal proteins. Patients with AN generally respond poorly to immunoglobulin therapy, and as a newly defined condition, there are currently no established treatment guidelines. Although rituximab shows potential as a therapeutic option, its high cost, limited availability, and the need for infusion monitoring hinder its use as a first-line treatment in many countries.
View Article and Find Full Text PDFPeripheral Immune-Mediated Neuropathy Before and During the COVID-19 Pandemic: A Retrospective Cross-Sectional Study in a Referral Center.
Cureus
November 2024
Center for Neurodiagnostic and Therapeutic Services, Metropolitan Medical Center, Manila, PHL.
Background: There are currently seven coronaviruses that can infect humans and the latest addition to these viruses is the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Infection by SARS-CoV-2 is known commonly as coronavirus disease 2019 (COVID-19). Aside from common manifestations of cough and fever, neurologic symptoms such as headache, disturbed consciousness, paresthesia, and seizures have also been seen.
View Article and Find Full Text PDFAssessing hand motor function in chronic immune-mediated neuropathies: a proof-of-concept study using a data glove.
J Neuroeng Rehabil
December 2024
Department of Neurology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Background: Chronic immune-mediated neuropathies are clinically heterogeneous and require regular, objective, and multidimensional monitoring to individualize treatment. However, established outcome measures are insufficient regarding measurement quality criteria (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!